Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis
dc.contributor.author | Eryilmaz, Melek Karakurt | |
dc.contributor.author | Karaagac, Mustafa | |
dc.date.accessioned | 2024-02-23T14:27:00Z | |
dc.date.available | 2024-02-23T14:27:00Z | |
dc.date.issued | 2019 | |
dc.department | NEÜ | en_US |
dc.description.abstract | Abiraterone is an oral inhibitor of cytochrome P450 (17alpha)-hydroxylase/17,20 lyase (CYP17) complex critical to androgen production. Abiraterone in combination with prednisone is currently FDA approved for use in men with metastatic castration-resistant prostate cancer, both in the pre- and post-chemotherapy settings. This article discusses the treatment with abiraterone in a patient with metastatic castration-resistant prostate cancer on hemodialysis. | en_US |
dc.identifier.doi | 10.1177/1078155218818250 | |
dc.identifier.endpage | 2034 | en_US |
dc.identifier.issn | 1078-1552 | |
dc.identifier.issn | 1477-092X | |
dc.identifier.issue | 8 | en_US |
dc.identifier.pmid | 31694496 | en_US |
dc.identifier.scopus | 2-s2.0-85074625126 | en_US |
dc.identifier.scopusquality | Q3 | en_US |
dc.identifier.startpage | 2031 | en_US |
dc.identifier.uri | https://doi.org/10.1177/1078155218818250 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12452/14418 | |
dc.identifier.volume | 25 | en_US |
dc.identifier.wos | WOS:000494855400030 | en_US |
dc.identifier.wosquality | Q4 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | Sage Publications Ltd | en_US |
dc.relation.ispartof | Journal Of Oncology Pharmacy Practice | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Abiraterone | en_US |
dc.subject | Metastatic Castration-Resistant Prostate Cancer | en_US |
dc.subject | Hemodialysis | en_US |
dc.title | Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis | en_US |
dc.type | Article | en_US |